Tetraphase Pharmaceuticals

Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVA^TM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.